Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus

mBio

Volumn 4, Issue 4, 2013, Pages

  Henningham, Anna ^a,e   Ericsson, Daniel J ^a   Langer, Karla ^a   Casey, Lachlan W ^a   Jovcevski, Blagojce ^b   Singh Chhatwal, G ^c   Aquilina, J Andrew ^b   Batzloff, Michael R ^d   Kobe, Bostjan ^a   Walker, Mark J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d GRIFFITH UNIVERSITY   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ARGININE DEIMINASE; MUTANT PROTEIN; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 4; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOSAFETY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; EPITOPE MAPPING; GENE MUTATION; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNOGENICITY; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE; SITE DIRECTED MUTAGENESIS; STREPTOCOCCUS GROUP A;

MUS; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

EID: 84883438399     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00509-13     Document Type: Article

References (51)

1. Henningham A, Barnett TC, Maamary PG, Walker MJ. 2012. Pathogenesis of group A streptococcal infections. Discov. Med 13:329-342.
2. Cole JN, Barnett TC, Nizet V, Walker MJ. 2011. Molecular insight into invasive group A streptococcal disease. Nat. Rev. Microbiol. 9:724-736.
3. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470-511.
4. Henningham A, Gillen CM, Walker MJ. 2013. Group A streptococcal vaccine candidates: potential for the development of a human vaccine. Curr. Top. Microbiol. Immunol. 368:207-242.
5. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB. 2004. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase I trial. JAMA 292:709-715.
6. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB. 2005. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41: 1114-1122.
7. McMillan DJ, Drèze PA, Vu T, Bessen DE, Guglielmini J, Steer AC, Carapetis JR, Van Melderen L, Sriprakash KS, Smeesters PR. 2013. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin. Microbiol. Infect. 19:E222-E229.
8. Smeesters PR, McMillan DJ, Sriprakash KS, Georgousakis MM. 2009. Differences among group A Streptococcus epidemiological landscapes: consequences for M protein-based vaccines? Expert Rev. Vaccines 8:1705-1720.
9. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. 2009. Global emm type distribution of group A Streptococci: systematic review and implications for vaccine development. Lancet Infect. Dis. 9:611-616.
10. Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, Ramachandran V, Cork AJ, Hartas J, Magor G, Djordjevic SP, Cordwell SJ, Kobe B, Sriprakash KS, Nizet V, Chhatwal GS, Margarit IY, Batzloff MR, Walker MJ. 2012. Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J. Mol. Med. 90:1197-1207.
11. Degnan BA, Fontaine MC, Doebereiner AH, Lee JJ, Mastroeni P, Dougan G, Goodacre JA, Kehoe MA. 2000. Characterization of an isogenic mutant of Streptococcus pyogenes Manfredo lacking the ability to make streptococcal acid glycoprotein. Infect. Immun. 68:2441-2448.
12. Curran TM, Lieou J, Marquis RE. 1995. Arginine deiminase system and acid adaptation of oral streptococci. Appl. Environ. Microbiol. 61: 4494-4496.
13. Ji Y, Carlson B, Kondagunta A, Cleary PP. 1997. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect. Immun. 65:2080-2087.
14. Chiarot E, Faralla C, Chiappini N, Tuscano G, Falugi F, Gambellini G, Taddei A, Capo S, Cartocci E, Veggi D, Corrado A, Mangiavacchi S, Tavarini S, Scarselli M, Janulczyk R, Grandi G, Margarit I, Bensi G. 2013. Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence. mBio 4:e00387-12. doi:10.1128/ mBio.00387-12.
15. Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M, Capo S, Falugi F, Manetti AG, Donato P, Swennen E, Gallotta M, Garibaldi M, Pinto V, Chiappini N, Musser JM, Janulczyk R, Mariani M, Scarselli M, Telford JL, Grifantini R, Norais N, Margarit I, Grandi G. 2012. Multi high-throughput approach for highly selective identification of vaccine candidates: the group A Streptococcus case. Mol. Cell. Proteomics 11: M111.015693. doi:10.1074/mcp.M111.015693.
16. Turner CE, Kurupati P, Wiles S, Edwards RJ, Sriskandan S. 2009. Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine 27:4923-4929.
17. Gillen CM, Courtney HS, Schulze K, Rohde M, Wilson MR, Timmer AM, Guzman CA, Nizet V, Chhatwal GS, Walker MJ. 2008. Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete. J. Biol. Chem. 283: 6359-6366.
18. Ulrich RG. 2008. Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock. J. Immune Based Ther. Vaccines 6:8. doi:10.1186/ 1476-8518-6-8.
19. Das K, Butler GH, Kwiatkowski V, Clark AD, Yadav P, Arnold E. 2004. Crystal structures of arginine deiminase with covalent reaction intermediates; implications for catalytic mechanism. Structure 12: 657-667.
20. Galkin A, Kulakova L, Sarikaya E, Lim K, Howard A, Herzberg O. 2004. Structural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug target. J. Biol. Chem. 279:14001-14008.
21. Galkin A, Lu X, Dunaway-Mariano D, Herzberg O. 2005. Crystal structures representing the Michaelis complex and the thiouronium reaction intermediate of Pseudomonas aeruginosa arginine deiminase. J. Biol. Chem. 280:34080-34087.
22. Lu X, Li L, Wu R, Feng X, Li Z, Yang H, Wang C, Guo H, Galkin A, Herzberg O, Mariano PS, Martin BM, Dunaway-Mariano D. 2006. Kinetic analysis of Pseudomonas aeruginosa arginine deiminase mutants and alternate substrates provides insight into structural determinants of function. Biochemistry 45:1162-1172.
23. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, Sonbuchner LS, McDonald CH, Cook RG, Dou Y, Roeder RG, Clarke S, Stallcup MR, Allis CD, Coonrod SA. 2004. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306: 279-283.
24. Proost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S, Dillen C, Ronsse I, Conings R, Struyf S, Opdenakker G, Maudgal PC, Van Damme J. 2008. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J. Exp. Med. 205:2085-2097.
25. Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, Stallcup MR, Sato M, Thompson PR. 2006. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 45: 11727-11736.
26. Georgousakis MM, Hofmann A, Batzloff MR, McMillan DJ, Sriprakash KS. 2009. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein. Vaccine 27:6799-6806.
27. Nuccitelli A, Cozzi R, Gourlay LJ, Donnarumma D, Necchi F, Norais N, Telford JL, Rappuoli R, Bolognesi M, Maione D, Grandi G, Rinaudo CD. 2011. Structure-based approach to rationally design a chimeric protein for an effective vaccine against group B Streptococcus infections. Proc. Natl. Acad. Sci. U. S. A. 108:10278-10283.
28. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, Palumbo E, Veggi D, Ciucchi L, Cartocci E, Bottomley MJ, Malito E, Lo Surdo P, Comanducci M, Giuliani MM, Cantini F, Dragonetti S, Colaprico A, Doro F, Giannetti P, Pallaoro M, Brogioni B, Tontini M, Hilleringmann M, Nardi-Dei V, Banci L, Pizza M, Rappuoli R. 2011. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3:91ra62. doi:10.1126/scitranslmed.3002234.
29. Wei Y, Zhou H, Sun Y, He Y, Luo Y. 2007. Insight into the catalytic mechanism of arginine deiminase: functional studies on the crucial sites. Proteins 66:740-750.
30. Curran TM, Ma Y, Rutherford GC, Marquis RE. 1998. Turning on and turning off the arginine deiminase system in oral streptococci. Can. J. Microbiol. 44:1078-1085.
31. Ryan S, Begley M, Gahan CG, Hill C. 2009. Molecular characterization of the arginine deiminase system in Listeria monocytogenes: regulation and role in acid tolerance. Environ. Microbiol. 11:432-445.
32. Marouni MJ, Ziomek E, Sela S. 2003. Influence of group A streptococcal acid glycoprotein on expression of major virulence factors and internalisation by epithelial cells. Microb. Pathog. 35:63-72.
33. Degnan BA, Palmer JM, Robson T, Jones CE, Fischer M, Glanville M, Mellor GD, Diamond AG, Kehoe MA, Goodacre JA. 1998. Inhibition of human peripheral blood mononuclear cell proliferation by Streptococcus pyogenes cell extract is associated with arginine deiminase activity. Infect. Immun. 66:3050-3058.
34. Aziz RK, Pabst MJ, Jeng A, Kansal R, Low DE, Nizet V, Kotb M. 2004. Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol. Microbiol. 51:123-134.
35. Cork AJ, Jergic S, Hammerschmidt S, Kobe B, Pancholi V, Benesch JL, Robinson CV, Dixon NE, Aquilina JA, Walker MJ. 2009. Defining the structural basis of human plasminogen binding by streptococcal surface enolase. J. Biol. Chem. 284:17129-17137.
36. Kabsch W. 2010. XDS. Acta Crystallogr. D Biol. Crystallogr. 66:125-132.
37. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40: 658-674.
38. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Pythonbased system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213-221.
39. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of COOT. Acta Crystallogr. D Biol. Crystallogr. 66:486-501.
40. Smart OS, Womack TO, Flensburg C, Keller P, Paciorek W, Sharff A, Vonrhein C, Bricogne G. 2012. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D Biol. Crystallogr. 68:368-380.
41. Afonine PV, Grosse-Kunstleve RW, Chen VB, Headd JJ, Moriarty NW, Richardson JS, Richardson DC, Urzhumtsev A, Zwart PH, Adams PD. 2010. Phenix. model_vs_data: a high-level tool for the calculation of crystallographic model and data statistics. J. Appl. Crystallogr. 43:669-676.
42. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66:12-21.
43. Konarev PV, Petoukhov MV, Volkov VV, Svergun DI. 2006. ATSAS, p 2.1, a program package for small-angle scattering data analysis. J. Appl. Crystallogr. 39:277-286.
44. Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI. 2003. PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J. Appl. Crystallogr. 36:1277-1282.
45. Petoukhov MV, Franke D, Shkumatov AV, Tria G, Kikhney AG, Gajda M, Gorba C, Mertens HDT, Konarev PV, Svergun DI. 2012. New developments in the ATSAS program package for small-angle scattering data analysis. J. Appl. Crystallogr. 45:324-350.
46. Fischer H, De Oliveira Neto M, Napolitano HB, Polikarpov I, Craievich AF. 2009. Determination of the molecular weight of proteins in solution from a single small-angle X-ray scattering measurement on a relative scale. J. Appl. Crystallogr. 43:101-109.
47. Svergun D, Barberato C, Koch MHJ. 1995. CRYSOL-a program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates. J. Appl. Crystallogr. 28:768-773.
48. Petoukhov MV, Svergun DI. 2005. Global rigid body modeling of macromolecular complexes against small-angle scattering data. Biophys. J. 89:1237-1250.
49. Knipp M, Vasák M. 2000. A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline. Anal. Biochem. 286:257-264.
50. Horikoshi N, Tachiwana H, Saito K, Osakabe A, Sato M, Yamada M, Akashi S, Nishimura Y, Kagawa W, Kurumizaka H. 2011. Structural and biochemical analyses of the human PAD4 variant encoded by a functional haplotype gene. Acta Crystallogr. D Biol. Crystallogr. 67:112-118.
51. Cole JN, Aquilina JA, Hains PG, Henningham A, Sriprakash KS, Caparon MG, Nizet V, Kotb M, Cordwell SJ, Djordjevic SP, Walker MJ. 2007. Role of group A Streptococcus HtrA in the maturation of SpeB protease. Proteomics 7:4488-4498.